GNI Group FY2023 revenue up 49% to ¥26.0B; Gyre expects Hydronidone IND in 2024; settles litigation for $385K

GYRE THERAPEUTICS, INC.

2023-FY EPS reported -$1.41 revenue$113,450,000

GNI Group FY2023 revenue ¥26,010M (+49% YoY), operating profit ¥13,108M (+851%), net profit ¥9,504M vs loss prior year.
Basic EPS ¥169.50; FY2024 guidance: revenue ¥39,566M (+52%), operating profit ¥16,286M.
Gyre expects to submit Hydronidone IND in US by end of 2024; Phase 3 trial in China last patient observation in 2024.
Gyre (as successor to Catalyst) settles shareholder litigation over business combination; pays $385K in attorneys' fees.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GYRE THERAPEUTICS, INC. reported FY2023 (January to December) results: revenue 26,010, net income 9,504, EPS 169.50. Guidance reaffirmed.

Period: FY2023 (January to December)
Revenue: 26,010
Net income: 9,504
EPS: 169.50
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

Profit attributable to owners of the parent Total comprehensive income for the year Million yen % Million yen % Million yen % Million yen % Million yen % Million yen % FY2023 26,010 49.3 13,108 851.3 12,612 - 9,504 - 8,094 - 10,662 - FY2022 17,418 37.3 1,377 (15.2) 767 (30.6) (868) - 388 (63.5) 187 (88.1) Basic earnings per share Diluted earnings per share

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

GYRE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-008051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.